Less Ads, More Data, More Tools Register for FREE

Pin to quick picksValiRx Regulatory News (VAL)

Share Price Information for ValiRx (VAL)

Share Price is delayed by 15 minutes
Get Live Data
0.15    -0.005 (-3.23%)
Bid:
0.14
Ask:
0.16
Spread: 0.02 (14.286%)
Market Cap: £1.98m
VAL Live PriceLast checked at - London Stock Exchange

Intraday ValiRx Share Chart

Issue of Equity

16 Aug 2010 17:12

RNS Number : 1576R
ValiRx PLC
16 August 2010
 



ValiRx Plc

("ValiRx" or the "Company")

 

 

Issue of Equity

 

ValiRx announces that, on 13 August 2010, the Company issued 7,407,333 new ordinary shares of 0.1p each ("Ordinary Shares") to Cancer Research Technology Limited ("CRT") at an issue price of 0.45p per share, being the mid-market price of the Ordinary Shares on 13 August 2010. The share issue was in respect of the payment of milestones and other payments due to CRT according to the terms and conditions of the option agreement entered into in 2008 with CRT and the subsequent licensing agreement with CRT signed on 11 August 2010.

 

Application has been made for the new Ordinary Shares to be admitted to trading on AIM and dealings are expected to commence on 19 August 2010. Following the issue of the new Ordinary Shares, the total number of Ordinary Shares now in issue is 343,923,790.

 

 

For further information, please contact:

 

ValiRx plc

Dr. Satu Vainikka

Tel: +44 (0) 20 3008 4416

www.ValiRx.com

WH Ireland Limited - Nominated Adviser

Robin Gwyn

Tel: +44 (0) 161 832 2174

Hybridan LLP - Broker

Claire Noyce

Tel: +44 (0) 207 947 4350

Peckwater PR

Tarquin Edwards

Tel: +44 (0)7879 458 364

tarquin.edwards@peckwaterpr.co.uk

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
IOEQQLFFBVFFBBF
Date   Source Headline
26th Jun 201912:00 pmRNSHolding(s) in Company
26th Jun 20197:00 amRNSUS Notice of Allowance-VAL201 & Metastatic Cancer
25th Jun 20192:50 pmRNSFurther re: Termination of Subscription Agreement
24th Jun 201912:45 pmRNSHolding(s) in Company
21st Jun 201912:00 pmRNSHolding(s) in Company
20th Jun 20197:00 amRNSUpdate on VAL201 Clinical Trial
19th Jun 201912:00 pmRNSHolding(s) in Company
13th Jun 20197:00 amRNSPlacing, Subscription Agreement & Issue of Warrant
10th Jun 20197:00 amRNSSubscription Agreement Update
5th Jun 20197:00 amRNSNotice of AGM & Update of Subscription Agreement
31st May 201911:07 amRNSSubscription Agreement Update
31st May 201910:42 amRNSHolding(s) in Company
30th May 201910:30 amRNSHolding(s) in Company
29th May 201911:44 amRNSHolding(s) in Company
29th May 20197:00 amRNSFinal Results
28th May 20197:00 amRNSSubscription Agreement Update
23rd May 201912:02 pmRNSHolding(s) in Company
22nd May 20197:00 amRNSSubscription Agreement Update
13th May 20192:00 pmRNSPrice Monitoring Extension
2nd May 20197:00 amRNSAcquisition of Intellectual Property& JV Agreement
29th Apr 20192:06 pmRNSSecond Price Monitoring Extn
29th Apr 20192:01 pmRNSPrice Monitoring Extension
29th Apr 201911:07 amRNSSecond Price Monitoring Extn
29th Apr 201911:01 amRNSPrice Monitoring Extension
29th Apr 201910:55 amRNSHolding(s) in Company
26th Apr 20197:00 amRNSSubscription, Convertible Funds and Warrant Issue
15th Apr 20197:15 amEQSHardman & Co Research: Valirx (VAL): VAL401 is going forward
26th Mar 20197:00 amRNSValiSeek Update
21st Mar 20197:00 amRNSUpdate on VAL201 & VAL301 Development Progress
21st Feb 201911:22 amRNSPlacing, Issue of Equity and Warrant
31st Jan 20197:00 amRNSNew patent grant allowances for VAL301
11th Jan 20197:00 amRNSPublication of VAL401 peer-reviewed article
9th Jan 201910:41 amRNSValiRx endorses the Government's new NHS strategy
3rd Jan 20197:00 amRNSHolding(s) in Company
18th Dec 20184:41 pmRNSSecond Price Monitoring Extn
18th Dec 20184:36 pmRNSPrice Monitoring Extension
18th Dec 201811:25 amRNSIssue of Equity / PDMR Shareholdings
18th Dec 20187:00 amRNSUpdate on VAL401 - Peer-review Acceptance
10th Dec 20187:00 amRNSUpdate on VAL201 Clinical Trial
5th Nov 20187:00 amRNSRe scientific and investor meetings
1st Nov 20187:15 amEQSHardman & Co Research: ValiRx (VAL): VAL401 Phase II trial completed
24th Oct 20187:00 amRNSAlign Research Initiates Coverage
17th Oct 20187:00 amRNSVAL201 in concluding stages of Phase I/II trial
15th Oct 201812:00 pmRNSVAL401 results shortly to be on ClinicalTrials.gov
25th Sep 20187:00 amRNSHalf-year Report
14th Sep 201812:42 pmRNSIssue of Equity
6th Sep 20187:00 amRNSUpdate on Clinical Development
24th Jul 201812:17 pmRNSResult of General Meeting
17th Jul 20187:00 amRNSUS PATENT GRANT FOR THERAPEUTIC COMPOUND, VAL301
6th Jul 20184:42 pmRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.